Walter Reed Army Institute of Research
Anthony Handlon has a diverse and extensive work experience in the pharmaceutical industry. Anthony is currently serving as the Principal Scientist of Medicinal Chemistry at the Walter Reed Army Institute of Research since 2022. Prior to this, they worked at GSK US as a Scientific Leader from 2015 to 2022 and as a Senior Research Investigator from 2013 to 2015. In 2012, they held the position of Dermatology Targets Manager/Research Program Leader at Stiefel, a GSK company. Anthony started their career at GlaxoSmithKline in 1995 and held various roles including Section Head from 2009 to 2012, Group Manager from 2001 to 2009, Research Investigator II from 2000 to 2001, Research Investigator I from 1996 to 2000, and Senior Scientist from 1995 to 1996. Prior to joining GSK, they worked as a Research Scientist III at Burroughs Wellcome Co. from 1993 to 1995.
Anthony Handlon has a strong background in chemistry. Anthony completed their post-doctoral studies at Duke University, earning a degree in chemistry. Prior to that, they obtained their Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco. Anthony's undergraduate degree is a Bachelor of Arts in Chemistry from Case Western Reserve University. Additionally, they attended Hawken School, although no specific degree or field of study was mentioned. In terms of certifications, Anthony has obtained various IT and software-related certificates, such as the Google IT Support Certificate and the Google IT Support Professional Certificate from Coursera and Google, respectively. Anthony has also completed several courses on Microsoft Teams and OneNote Online through LinkedIn.
This person is not in any offices
Walter Reed Army Institute of Research
WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations. Through both times of peace and war, infectious diseases have killed, sickened, and disabled far more Service Members than bombs and bullets. WRAIR has created a model of vaccine and therapeutic development that is unique, nimble, and responsive to dynamically evolving infectious disease threats of military importance. WRAIR, with its unparalleled expertise, facilities, and international network, has developed many vaccines and drugs in use today by military and civilian medicine around the globe. In addition to protecting against infectious disease threats, WRAIR conducts basic and applied research that promotes psychological resilience, enhances neurological functioning, and improves operational readiness among U.S. Service Members. By using a continuum of research from basic science to applied field studies, WRAIR creates innovative solutions to enhance Service Members’ resilience and recovery. Research in military psychiatry and neuroscience has been an integral part of WRAIR's portfolio for more than 70 years. WRAIR researchers are recognized leaders in operational medical research for the military in a number of fields, including brain trauma, blast exposure, deployment stressors, and sleep management.